Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 14, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the company will present a corporate overview and business update at the 2017 Wedbush PacGrow Healthcare Conference at 10:55am ET on Wednesday, August 16, 2017, at Le Parker Meridien in New York.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858-717-2310 Email: [email protected]
